Contact
01For health systems

For high-volume emergency departments, the cost of the current ACS observation pathway is measured in boarding hours, bed-days, and throughput drag.

Infrasensor compresses time-to-identification for high-grade obstructive cases — accelerating the patients who need intervention toward it, and providing an objective AI-enabled signal that reduces variability in early decision-making.

02The pathway in system terms
3–12+ hrs
ED observation consumed per chest-pain patient before identification[1]
18.8–25.0 hrs
Average ED observation length of stay for chest pain[2]
48–72 hrs
Average time to catheterisation, NSTEMI (delayed arm)[4]
03Three value pillars
Pathway compression

Fewer observation hours consumed by true-positive patients who were going to need intervention anyway.

Procedural revenue acceleration

Earlier cath-lab activation means faster PCI revenue capture for identified cases.

Outcome cost avoidance

Less myocardial damage means shorter post-procedure length of stay and fewer heart-failure readmissions.

04Value by stakeholder
StakeholderValue from earlier identification
PatientReduced time-to-intervention for severe coronary occlusion; reduced myocardial damage from delay
Emergency physicianRapid, non-invasive signal at initial encounter — before hours-long serial protocol completes; removes reliance on symptom subjectiveness and risk-score subjectivity
Cardiologist / interventionalistEarlier cath-lab activation for confirmed high-grade obstruction
Health system / CFOFaster throughput for identified patients; reduced boarding hours; improved bed utilization; stronger case-mix capture on interventional cases
Quality / CMOObjective, AI-enabled adjunct reduces variability in early identification; supports quality metrics for time-to-intervention
05In summary

Infrasensor compresses time-to-identification for high-grade obstructive cases — accelerating the patients who need intervention toward it, and providing an objective AI-enabled signal that reduces variability in early decision-making.

HOURSMINUTESELAPSED TIME →
Sources
  1. NSTEMI: The Latest Evidence in Emergency Department Management, EB Medicine, 2024
  2. Emory Emergency Department Clinical Decision Unit data
  3. ACEP / Annals of Emergency Medicine, October 2024
  4. Kite et al., Heart (BMJ), 2024 — RAPID NSTEMI
  5. TIMACS
  6. VERDICT

Infrasensor is an investigational device. Not yet cleared by the FDA. Pursuing Class II De Novo approval; submission anticipated 2026.